Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 2,637 Shares

Key Points

• Insider Soleil Boughton sold 2,637 shares of Hims & Hers Health at an average price of $54.38, totaling approximately $143,400, which decreased their position by 1.61%.
• Hims & Hers Health stock experienced a 1.1% decline, trading at $54.12, with a market capitalization of $12.23 billion and a P/E ratio of 67.65.
• The company reported earnings of $0.17 per share, missing estimates by $0.01, with quarterly revenue of $544.83 million, up 72.6% from the previous year.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,637 shares of the stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $54.38, for a total transaction of $143,400.06. Following the sale, the insider owned 161,130 shares of the company's stock, valued at $8,762,249.40. This trade represents a 1.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, September 29th, Soleil Boughton sold 2,637 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.79, for a total transaction of $155,029.23.
• On Wednesday, September 17th, Soleil Boughton sold 2,637 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.50, for a total transaction of $133,168.50.
• On Monday, August 25th, Soleil Boughton sold 2,571 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.53, for a total transaction of $114,486.63.
• On Monday, August 11th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $51.64, for a total value of $132,818.08.
• On Monday, July 28th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.70, for a total transaction of $150,976.40.

Hims & Hers Health Stock Down 1.1%

NYSE HIMS traded down $0.61 on Tuesday, reaching $54.12. The company had a trading volume of 21,057,855 shares, compared to its average volume of 32,557,629. The stock has a market capitalization of $12.23 billion, a P/E ratio of 67.65, a P/E/G ratio of 3.65 and a beta of 2.25. Hims & Hers Health, Inc. has a 52-week low of $18.33 and a 52-week high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The company's fifty day moving average is $50.69 and its 200 day moving average is $48.29.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same period in the previous year, the firm earned $0.06 EPS. The firm's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its stake in shares of Hims & Hers Health by 121.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 19,005 shares of the company's stock valued at $1,078,000 after purchasing an additional 10,421 shares during the last quarter. Jamison Private Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $237,000. Matauro LLC raised its position in Hims & Hers Health by 5.9% in the 3rd quarter. Matauro LLC now owns 9,470 shares of the company's stock worth $537,000 after buying an additional 528 shares during the last quarter. Kessler Investment Group LLC increased its position in shares of Hims & Hers Health by 6.4% during the 3rd quarter. Kessler Investment Group LLC now owns 122,612 shares of the company's stock valued at $6,955,000 after purchasing an additional 7,338 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in Hims & Hers Health by 47.0% in the 3rd quarter. Voya Investment Management LLC now owns 163,773 shares of the company's stock worth $9,289,000 after purchasing an additional 52,370 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday, June 23rd. Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Canaccord Genuity Group restated a "buy" rating and issued a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Hims & Hers Health in a report on Tuesday. Finally, Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average target price of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.